Dendreon plans to raise $59M to market Provenge

Dendreon plans to sell 10 million shares of common stock in a deal aimed at raising $59 million before expenses. The Seattle-based drug developer will use much of the money to commercialize its experimental prostate-cancer drug Provenge, which it plans to file an application on next year.

- read this article from the Seattle Times for more information

ALSO: Dendreon has agreed to a special protocol assessment amendment for its ongoing Phase III trial of Provenge. Release